Yahoo Canada Web Search

Search results

  1. DANIEL L. DOCTOROFF. Having lost both his father and uncle to ALS, Daniel L. Doctoroff founded Target ALS, a transformative biomedical research nonprofit, in 2013 to accelerate discovery of effective treatments for ALS. In October 2021, Dan himself was diagnosed with ALS. Upon receiving the news, his focus shifted to scaling up the organization.

    • daniel l. doctoroff - new jersey office phone number calgary customer service1
    • daniel l. doctoroff - new jersey office phone number calgary customer service2
    • daniel l. doctoroff - new jersey office phone number calgary customer service3
    • daniel l. doctoroff - new jersey office phone number calgary customer service4
    • daniel l. doctoroff - new jersey office phone number calgary customer service5
  2. View Dan Doctoroffs profile on LinkedIn, a professional community of 1 billion members. I'm the Founder and Chairman of Target ALS, a research foundation dedicated to…

    • 500+
    • Target ALS
    • 10K
    • New York, New York, United States
  3. Daniel Louis Doctoroff (born July 11, 1958 [1]) is an American businessman and former government official. [2] From 2015 to 2021, he served as Chief Executive Officer of Sidewalk Labs, a startup company he helped found focused on technology for city life.

  4. May 2, 2024 · Find out why Dan Doctoroff is on the TIME100 Health list.

  5. See who you know in common. Get introduced. Contact Daniel directly. Chairman at Target ALS · Experience: Target ALS · Location: 10002. View Daniel Doctoroffs profile on LinkedIn, a...

    • Target ALS
  6. Daniel L. Doctoroff - Target ALS. Share. Founder and Board Chair. Read more Interesting and Inspiring Articles. NEWS: Target ALS Biosample Recipients Identify Three Distinct Subtypes of ALS. Target ALS and The ALS Association Announce New TDP-43-Focused Biomarker Initiative. Target ALS Annual Meeting Canceled Due to the Spread of COVID-19. Join Us.

  7. Doctoroff and his team created a new collaborative model of research that has been a major catalyst to understanding the genetics and biology of ALS and has lowered the barriers to entry for new scientific discovery, and has helped to induce over 100 biotech, pharmaceutical, and venture capital firms to demonstrate interest in the disease.